Enrollment completed in separate Phase II study in Carotid Atherosclerosis
LEXINGTON, Mass., Oct. 24 /CNW/ -- ActivBiotics, Inc. today announced
that the results of its pivotal clinical trial (PROVIDENCE-1) studying the
effect of rifalazil in the treatment of intermittent claudication associated
with peripheral arterial disease (PAD) will be presented on November 7, 2007
at 11:45 a.m. EST at a late breaker Scientific Session at the American Heart
Association's 2007 annual meeting being held in Orlando, Florida. Michael R.
Jaff, DO, FACP, FACC, Assistant Professor of Medicine, Harvard Medical School
and Medical Director, Massachusetts General Hospital Vascular Center, Boston,
Massachusetts, Chair of the trial's Steering Committee, will be presenting.
PROVIDENCE-1 (Prospective Evaluation of Rifalazil Effect on Vascular
Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia
Seropositive Patients) is the first of two planned Phase III clinical trials
to study the ability of rifalazil to improve symptoms in patients suffering
from intermittent claudication, an often debilitating and under diagnosed
manifestation of PAD. The prospective, double-blind, randomized, placebo-
controlled trial evaluated the efficacy and safety of rifalazil in 297
patients from the United States, Russia and Brazil. The FDA has granted
rifalazil Fast Track designation for development in this indication.
In addition to the PROVIDENCE-1 Phase III clinical trial, a Phase II
study to evaluate the effect of rifalazil on the progression of carotid artery
atherosclerosis has completed its target enrollment of 72 patients. The
RESTORE-IT trial (Randomized Evaluation of Short-Term Rifalazil Treatment on
Carotid Atherosclerosis and Intima Media Thickness) is a prospective,
randomized, double-blind, placebo-controlled, multi-center study of patients
with a clinical history of atherosclerosis and image-detectable carotid
disease. This study will use the non-invasive imaging techniques of combined
high-resolution magnetic resonance imaging and ultrasound to assess the degree
of architectural changes in the carotid artery brought about by rifalazil
treatment. The presence and progression of carotid disease are strongly
correlated with an increased incidence of cardiovascular and stroke events.
Chlamydia pneumoniae infection of the vascular system has long been
thought to play a role in accelerating the course of vascular disease
potentially by increasing inflammation in the arterial wall thus leading to
exacerbation of atherosclerosis, which could reduce blood supply to target
limbs and organs.
About ActivBiotics, Inc.
ActivBiotics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of therapies for the treatment of
inflammatory diseases and bacterial infections. For more information on
ActivBiotics, Inc., please visit our web site at: http://www.activbiotics.com.
Safe Harbor Statement
This press release may contain or incorporate by reference certain
statements that are not historical facts, including statements preceded by,
followed by or that include the words "may," "believes," "will", "expects,"
"anticipates" or the negation thereof, or similar expressions, which
constitute "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements
that address events, transactions or developments that are expected or
anticipated to occur in the future are forward-looking statements within the
meaning of the Reform Act. Such forward-looking statements involve risks,
uncertainties and other factors that may cause the actual performance or
achievements of ActivBiotics, Inc. to be materially different from any future
results, performance or achievements expressed or implied by such forward-
looking statements. For those statements, ActivBiotics, Inc. claims the
protection of the safe harbor for forward-looking statements contained in the
Reform Act. ActivBiotics, Inc. will not undertake and specifically declines
any obligation to publicly release the result of any revisions that may be
made to any forward-looking statements to reflect events or circumstances
after the date of such statements or to reflect the occurrence of anticipated
or unanticipated events.
For further information:
For further information: Glenn Kazo, Chief Business Officer,
+1-781-372-4864, firstname.lastname@example.org; or Christina DiCarlo, Manager,
Corporate Communications, +1-781-372-4807, email@example.com, both of
ActivBiotics, Inc. Web Site: http://www.activbiotics.com/